Fig. 2.

Kaplan–Meier curve of progression-free survival (a) and hazard ratios of progression-free survival (b) in patients with leiomyosarcoma. CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance score, HR hazard ratio (eribulin to dacarbazine), based on a Cox regression model including treatment as a covariate and stratification factors of geographic region and number of prior chemotherapy regimens, LMS leiomyosarcoma, STS soft tissue sarcoma. ^a Region 1 = USA and Canada; Region 2 = Western Europe, Australasia, and Israel; Region 3 = Eastern Europe, Latin America, and Asia